How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

681 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

241. A Study to Characterise the Physiology of Weight Loss and Regain Under Dietary, Behavioural and Pharmacological Interventions in Healthy Obese Subjects

composition during and after three interventions (i) calorie restricted diet + a marketed anti-obesity drug (sibutramine )(ii) calorie restricted diet + sibutramine placebo, and (iii) calorie restricted diet + moderate exercise. The interventions will last 12 weeks, after which there is a further 12 week observation period during which subjects will return to their normal lifestyle and are expected to regain weight. Additionally, a range of biomarkers may be evaluated to determine whether (...) , Sussex Ingestion Pattern Monitor ™ (SIPM), hunger-satiety VAS, indirect calorimetry and, if available, the Theranos in-home graphical user interface (GUI) portal. Knowledge of the body composition changes resulting from these typical weight loss interventions and predictive markers of response would facilitate the design of future studies for novel anti-obesity agents and allow earlier, more informed triaging of NCEs. Condition or disease Intervention/treatment Phase Obesity Drug: sibutramine Other

2012 Clinical Trials

242. Full4Health: Understanding Food-gut-brain Axis Across the Lifecourse

disease Multiple Sclerosis Parkinsons disease Medication known to influence appetite (orlistat, oral antidiabetics, insulin, digoxin, anti-arrhythmics, sibutramine, antidepressants) Self report fever/systemic infection Inability to participate in fMRI scanning sessions including contraindications to MRI Participation in medical or surgical weight loss programme within 1 month of selection History of cerebrovascular disease Current major depressive disorder, bipolar disorder or past history of suicide

2012 Clinical Trials

243. Effect of the G-protein β(3) subunit 825T allele on the change of body adiposity in obese female. (Abstract)

Effect of the G-protein β(3) subunit 825T allele on the change of body adiposity in obese female. No clinical studies on the lipolytic effect of guanine nucleotide-binding protein β3 subunit gene (GNB3) 825T polymorphism have been performed. This study was a subinvestigation of a 12-week randomized controlled trial (NCT01184560) for the additive effect of orlistat on sibutramine treatment. The analysis involved 101 obese females aged 18-49 years, genotyped at the GNB3 825 locus. To exclude any

2012 obesity & metabolism Controlled trial quality: uncertain

244. Natural drugs aren’t necessary safe. Don’t make that mistake.

with anabolic steroids. Some of these contaminated supplements were Vitamin C and magnesium tablets. They also found that nutritional supplements were adulterated with the stimulants ephedrine, caffeine, methylenedioxymethamphetamine (MDMA, “ecstasy”) and sibutramine (Meridia, a prescription-only weight loss drug). This is a problem unique to the United States. In Europe, the herbal industry is as stringently regulated as the prescription medication industry. When a person purchases an herbal remedy from

2015 KevinMD blog

245. What is the Role of Drug Therapy in Treating Obesity?

or surgery. 7 Medications used for obesity treatment, including those still under development, aim to reduce calorie absorption or decrease appetite. The FDA has approved two drugs for the induction and long-term maintenance of weight loss. Sibutramine ( Meridia ) reduces appetite by inhibiting the reuptake of norepinephrine and serotonin in the central nervous system. The other approved medication, orlistat ( Xenical , Alli ), blocks peripheral absorption of calories in the form of fat by inhibiting (...) weight-loss treatments. The selective cannabinoid-1 receptor antagonist rimonabant initially promised to deliver superior results to sibutramine and orlistat, particularly with regard to improvements in HDL, triglycerides, and glucose tolerance. Rimonabant reduces appetite and results in a 4.7 kg weight loss over one year compared to placebo. Although rimonabant initially received approval in Europe, in October 2008 the European Medicines Agency withdrew marketing authorization due to the emergence

2009 Clinical Correlations

246. A two-year randomized trial of obesity treatment in primary care practice. Full Text available with Trip Pro

replacements or weight-loss medication (orlistat or sibutramine), chosen by the participants in consultation with the PCPs, to potentially increase weight loss.Of the 390 participants, 86% completed the 2-year trial, at which time, the mean (±SE) weight loss with usual care, brief lifestyle counseling, and enhanced brief lifestyle counseling was 1.7±0.7, 2.9±0.7, and 4.6±0.7 kg, respectively. Initial weight decreased at least 5% in 21.5%, 26.0%, and 34.9% of the participants in the three groups (...) , respectively. Enhanced lifestyle counseling was superior to usual care on both these measures of success (P=0.003 and P=0.02, respectively), with no other significant differences among the groups. The benefits of enhanced lifestyle counseling remained even after participants given sibutramine were excluded from the analyses. There were no significant differences between the intervention groups in the occurrence of serious adverse events.Enhanced weight-loss counseling helps about one third of obese

2011 NEJM Controlled trial quality: uncertain

247. Review: weight-reducing agents improve glycaemic control and reduce progression to diabetes

progression to diabetes Commentary Statistics from S Czernichow Dr S Czernichow, Unite de Recherche en Nutrition Humaine, Bobigny, France; QUESTION How do weight-reducing agents affect glycaemic parameters and risk of type 2 diabetes in predisposed individuals? REVIEW SCOPE Included studies were randomised, double-blind, placebo controlled trials (RCTs) that evaluated the effects of weight-reducing agents (eg, orlistat, sibutramine, and rimonabant

2009 Evidence-Based Nursing

248. Serotonin Syndrome

stimulants Amphetamine Cocaine Diethylpropion Methamphetamine 3,4-Methylenedioxyamphetamine (MDA) 3,4-Methylenedioxymethamphetamine (MDMA, or Ecstasy) Methylphenidate Phentermine Sibutramine Hallucinogens Lysergic acid diethylamide (LSD) 5-Methoxy-diisopropyltryptamine Herbs Nutmeg Panax (Asian or American) ginseng St John’s wort Syrian rue 5-Hydroxytryptamine (5-HT 1 ) agonists (triptans) Almotriptan Eletriptan Frovatriptan Naratriptan Rizatriptan Sumatriptan Zolmitriptan Opioids Buprenorphine Fentanyl

2013 Merck Manual (19th Edition)

249. Obesity

chestnut, chromium picolinate, fucus vesiculosus, and ginkgo biloba. Some (eg, caffeine, ephedrine, guarana, phenylpropanolamine) have adverse effects that outweigh their advantages. Also, some of these drugs are adulterated or contain harmful substances banned by the FDA (eg, ephedra, bitter orange, sibutramine). Surgery is the most effective treatment for extremely obese patients. Special Populations Obesity is a particular concern in children and the elderly. Children For obese children

2013 Merck Manual (19th Edition)

250. Lack of evidence to choose second line drug treatments for type 2 diabetes

glycaemic control. This systematic review set out to find out which is the most effective choice. The reviewers conducted a search of the main bibliographic databases and found 49 randomised trials relevant to the topic. These studies evaluated the effectiveness of sulfonylureas, meglitinides, thiazolidinediones, DPP-4 inhibitors, GLP-1 analogues, insulins and insulin analogues, alpha-glucosidase inhibitors and the weight-loss agents orlistat and sibutramine. The reviewers analysed combination

2011 The Diabetes Elf

251. Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus

cardiovascular dysfunction or history thereof within 12 months of screening; serious arrhythmia, treatment with medications to control/treat arrhythmias; myocardial infarction; cardiac surgery; history of valvular heart disease Previous or current use of amiodarone Treatment with glucagon-like peptide-1 (GLP-1) analogs, thiazolidinediones (TZD), or weight loss drugs (eg, sibutramine, orlistat) within 3 months of screening History of pulmonary embolism or deep venous thrombosis in the 12 months before

2011 Clinical Trials

252. Tomato Consumption and High Density Lipoprotein-cholesterol

, estrogens or progesterone), metformin, other oral hypoglycemic agents, insulin, sibutramine, or orlistat treatment and those with daily consumption of any non-steroidal anti-inflammatory drug were also excluded. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its identifier (NCT

2011 Clinical Trials

253. Calcium Supplementation for a Healthy Weight (CaSHeW)

within the last six months of medications that can result in significant weight gain or weight loss, including antipsychotics, selective serotonin reuptake inhibitors, anti-epileptic drugs, appetite-suppressants such as phentermine and sibutramine, and the lipase-inhibitor orlistat. Active eating disorder History of alcoholism or substance abuse within 5 years prior to study entry. Use of a dietary supplement or medication that decreases calcium absorption History of kidney stone, hyperparathyroidism

2011 Clinical Trials

254. The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS)

(AMH) levels in obese women with polycystic ovary syndrome (PCOS) and in obese controls. The other aim of the investigators study, was to examine the effect of hypocaloric diet,physical exercise plus sibutramine on serum AMH levels, body composition, hormonal and metabolic parameters in overweight and obese patients with polycystic ovary syndrome (PCOS). Condition or disease Intervention/treatment Phase Obesity Polycystic Ovaries Syndrome Drug: Orlistat Drug: Sibutramine Behavioral: Diet (...) and physical exercise Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 200 participants Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: The Effect of Weight Loss With Orlistat or Sibutramine Administration , Hypocaloric Diet and Physical Exercise , on AMH Levels, in Women With Polycystic Ovary Syndrome Study Start Date : January 2004

2011 Clinical Trials

255. Dextromethorphan for Diabetic Macular Edema

mesylates; ergotamine; escitalopram; fluoxetine; fluvoxamine; frovatriptan; imipramine; isocarboxazid; linezolid; lithium; maprotiline; meperidine; methylergonovine; milnacipran; mirtazapine; moclobemide; naratriptan; nefazodone; nortriptyline; paroxetine; phenelzine; procarbazine; promethazine; protriptyline; rasagiline; rizatriptan; SAMe (S-adenosylmethionine); selegiline; sertraline; sibutramine; St. Johns wort; sumatriptan; tapentadol; tramadol; tranylcypromine; trazodone; trimipramine; tryptophan

2011 Clinical Trials

256. Effect of Cocoa Consumption in Cardiovascular and Immune Parameters

Regular consumption of antioxidants, multivitamins, anti-inflammatory medications, drugs for nasal congestion and sibutramine Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its identifier (NCT number): NCT01496235 Locations Layout table for location information Colombia Sede

2011 Clinical Trials

257. A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)

over the counter supplements of fish oils within 6 weeks intends to consume at least 1.2 liters of grapefruit juice per day during the course of the study is on or is likely to require treatment with 14 consecutive days or more, or repeated courses of corticosteroids is on a weight loss program and not in the maintenance phase or has started a weight loss medication (such as orlistat or sibutramine) within the prior 8 weeks has undergone a surgical procedure within the prior 4 weeks has a history

2011 Clinical Trials

258. The Impact of Omega-3 Supplementation on Gene Expression in Type 2 Diabetics

the intervention Exclusion Criteria: people who have used omega-3 supplements in last 3 months Having chronic renal disease hepatic disease gastrointestinal disease hematological disorders hypothyroidism or hyperthyroidism Treatment with Orlistat or sibutramine for weight loss Pregnancy and lactation Treatment with insulin or Thiazolidinediones Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff

2011 Clinical Trials

259. Oro-gastro-intestinal Digestion of Emulsified Fat

, tricyclic antidepressants, narcotic analgetics, adrenergic agents, calcium channel blockers), or alter intestinal transit (e.g., loperamide, chemical/osmotic/bulk laxatives) or influence satiety/energy intake (e.g. sibutramine, glucocorticoids, anabolic steroids), except oral contraceptives Pregnancy, lactation, wish to become pregnant during study, or having a positive pregnancy test at inclusion Reported unexplained weight loss/gain of more than 2 kg in the month before the study enrollment Score > 9

2011 Clinical Trials

260. Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period

Current or previous chemotherapy or radiation therapy that may result in pulmonary toxicity; use of medications for weight loss (eg, sibutramine, orlistat) within 12 weeks of Screening; treatment with amiodarone within 12 weeks of Screening Clinically significant abnormalities on screening laboratory evaluation or chest x-ray Severe complications of diabetes, in the opinion of the PI, including symptomatic autonomic neuropathy; disabling peripheral neuropathy; active proliferative retinopathy

2011 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>